Sarcopenia
Conditions
Brief summary
Liver cancer poses a major threat to the global cancer burden, and the number of deaths is estimated to be more than one million annually by 2030. Locoregional therapies such as transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and radiation are associated with improved survival and quality of life for patients with unresectable HCC \[Couri and Pillai, 2019\]. However, curative therapies or locoregional therapies are not applicable to approximately 50% of HCC cases who are diagnosed at an advanced stage and have progression with transarterial therapies \[Park et al., 2015\]. For these patients, sorafenib, lenvatinib, and atezolizumab combined with bevacizumab have been approved as the first-line systemic therapy \[Fan et al., 2022\]. Sarcopenia is a progressive and generalized skeletal muscle disease characterized by accelerated loss of muscle mass and function \[Cruz-Jentoft and Sayer, 2019\]. It has been associated with higher mortality among the general population and patients with cancer. This study aims to assess the possible role of sarcopenia in predicting the outcome of HCC patients following a variety of treatments including local ablation, TACE and sorafenib.
Interventions
PROCEDURElocal ablation
treatment of HCC
PROCEDURETACE
treatment of HCC
DRUGSorafenib
treatment of HCC
Sponsors
Sohag University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Clinical diagnosis of hepatocellular carcinoma. 2. Treatment-naive patients who underwent local ablation, TACE or sorafenib as a primary treatment .
Exclusion criteria
1. Use of other another HCC treatment modality e.g., resection. 2. Use of combined treatments e.g., simultaneous use of embolic therapy with ablation. 3. Patients with recurrent HCC. 4. Patients with secondaries from extra-hepatic primary tumors. 5. Incomplete data at the diagnosis, treatment or follow up time-points. 6. Loss of patients follow up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | for at least 1 year from the treatment | time from treatment till death or last contact |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence-free survival | for at least 1 year from the treatment | time from HCC treatment to tumor relapse (identified by imaging) or last contact |
| Progression-free survival | for at least 1 year from the treatment | time from HCC treatment to tumor progression (identified by imaging) or last contact |
Outcome results
None listed